Table 6.
The number of studies that conducted further experimentation to gain further understanding of the cannabinoids, cannabis-based medicines, and endocannabinoid system modulators in conjunction with antinociceptive effect.
| No. of studies | % | |
|---|---|---|
| Confirmation (where applicable) of the CB1/CB2 target | 207 | 69 |
| Effects on motor activity | 124 | 33 |
| Investigate pharmacokinetics | 26 | 7 |
| Tissue concentrations | 25 | 7 |
| Electrophysiology | 20 | 5 |
| Potential toxic effects | 19 | 5 |
| Measure markers of neuronal activity | 19 | 5 |
| Effect on anxiety/depression | 11 | 3 |
| Effects on dependency | 10 | 3 |
CB2, cannabinoid type 2.